Almirall Will Sell Basilea's Eczema Drug In 10 European Markets, Plus Mexico
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's distribution agreement with Almirall does not change Basilea's 2010 sales guidance for its eczema drug Toctino, execs said.
You may also be interested in...
Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership
Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.